CClinicalTrials.gg
Status unknownNCT05539456Updated Sep 19, 2022

Reliability and Validity of the Turkish Version of the PedsQL 3.0 Neuromuscular Module for 2-to 4- Year-old

An observational study in Spinal Muscular Atrophy, Quality of Life and Neuromuscular Diseases, sponsored by Istanbul Medipol University Hospital. Status unknown at 1 site in Turkey. Open to participants aged 2 Years to 4 Years. Per ClinicalTrials.gov, last updated 2022-09-19.

Sponsored by Istanbul Medipol University Hospital · Observational

The sponsor has not verified this record recently (last verified Sep 2022), so the status shown — last known as Enrolling by invitation — may be out of date.
Study type
Observational
Model
Cohort
Time perspective
Prospective
Enrollment
55
Ages
2 Years to 4 Years
Sex
All
01

Study summary

The aim of the investigator's study was to investigate translating the PedsQL 3.0 Neuromuscular Module for 2-to 4- Year-old and using it in clinics reliably and validity with a Turkish version of the PedsQL Generic Core (Pediatric Quality of Life Questionnare) in children with Spinal Muscular Atrophy in Turkey

Read the detailed description

The PedsQL 3.0 Neuromuscular Module for 2-to 4- year-old will be translated into Turkish by following the language translation steps. First of all, the English form will be translated into Turkish by two people who are fluent in English. Then, the forms translated by another expert in the field will be reviewed. The revised text will be translated from Turkish into English by another person with a good command of English and will be compared with the original scale by the lecturer. If a significant change in meaning is not detected, the scale will be applied to 10 parents. In case of incomprehensible questions, which are reported to be lacking in expression, the scale will be finalized after revision and corrections are made by the research team.

02

Conditions studied

  • Spinal Muscular Atrophy
  • Quality of Life
  • Neuromuscular Diseases
  • Pediatric Disorder

Keywords

  • Spinal Muscular Atrophy
  • Quality of Life
  • Neuromuscular Diseases
03

In context

Muscular Atrophy

494 studies on the registry are indexed under Muscular Atrophy; 94 are open to participants now.

This study's planned enrollment of 55 is below the median of 72 across 139 observational studies indexed under Muscular Atrophy.

Browse Muscular Atrophy studies →

Lead sponsor

Istanbul Medipol University Hospital is the lead sponsor of 350 studies on the registry; 58 are open to participants now.

Counted across the registry records on this site, refreshed daily.

04

Who can participate

Ages eligible
2 Years to 4 Years
Sexes eligible
All
Accepts healthy volunteers
No
Sampling method
Non-probability sample

Study population

Children with spinal muscular atrophy between 2 to 4 years age.

Inclusion criteria

  • Having a child with spinal muscular atrophy
  • Having a child between the ages of 2-4
  • Accept to participate in the study

Exclusion criteria

Exclusion Criteria:

  • Lack of cooperation during work
  • Presence of disease other than SMA, which will prevent participation in the study
05

Study design

Observational model
Cohort
Time perspective
Prospective
Enrollment
55 participants (estimated)
Patient registry
No
06

What researchers measure

Primary outcomes

  1. PedsQLTM 3.0 neuromuscular module for 2-to 4- Year-old

    The module encompasses three scales: 1. About My/My Child's Neuromuscular Disease (17 items), 2. Communication (3 items), 3. About Our Family Resources (5 items). The scale is comprised a parent proxy-report format for children ages 2 to 4 years. Items in all forms are essentially identical but contain slightly different language for first or third person tense. The participants are asked how much of a problem each item had been during the past month. Responses are rated on a 5-point Likert scale across child self-report for children, teens, and parent proxy-reports (0 = never a problem, 1 = almost never a problem, 2 = sometimes a problem, 3 = often a problem, 4 = almost always a problem). Items are linearly transformed to a 0 to 100 scale (0 = 100, 1 = 75, 2 = 50, 3 = 25, and 4 = 0) so that higher scores indicate better HRQOL.

    Time frame: 5-10 minutes

Secondary outcomes

  1. PedsQLTM 4.0 generic core scales

    The 23-item PedsQLTM 4.0 Generic Core Scales encompass: 1. Physical Functioning (8 items), 2. Emotional Functioning (5 items), 3. Social Functioning (5 items), 4. School Functioning (5 items) The formats, instructions, Likert scales, and scoring methods are the same as those of the PedsQLTM 3.0 Neuromuscular Module. To create the Psychosocial Health Summary Score, the mean is computed as the sum of the items divided by the number of items answered in the Emotional, Social, and School Functioning Subscales.

    Time frame: 5-10 minutes

07

Study locations

1 site
  • Seval Kutlutürk Yıkılmaz
    Istanbul, Kavacık 34810, Turkey
08

Updates

Tracking since Sep 25, 2026
No changes since tracking began. The registry record was last updated on Sep 19, 2022, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
09

Registry details

Key details

Study ID
NCT05539456
Lead sponsor
Istanbul Medipol University Hospital
Responsible party
Sponsor
First posted
Sep 14, 2022
Start date
Sep 1, 2022
Primary completion
Oct 1, 2022 (estimated)
Completion
Nov 1, 2022 (estimated)
Last update
Sep 19, 2022

Study contacts

Seval Kutlutürk Yıkılmaz
principal investigator · Medipol University

Oversight

FDA-regulated drug
No
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is status unknown, as verified in Sep 2022. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Start the discussion